The goal of this study is to create new retinal imaging processing software useful for the development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's disease (AD).
Study Type
OBSERVATIONAL
Enrollment
60
Intervention same to all groups.
Duke University Medical Center
Durham, North Carolina, United States
Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score
The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline.
Time frame: Baseline
NFL/GCL abnormality score
The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have another measurement taken at 12 months.
Time frame: 12 months
Drusen/plaque score
The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subject groups at baseline.
Time frame: Baseline
Drusen/plaque score
The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subjects groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement at 12 months.
Time frame: 12 months
Total drusen area
The study will determine the significance of difference in total drusen area between the AD subject groups at baseline.
Time frame: Baseline
Total drusen area
The study will determine the significance of difference in total drusen area between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement taken at 12 months.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.